<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03839355</url>
  </required_header>
  <id_info>
    <org_study_id>17-010544</org_study_id>
    <nct_id>NCT03839355</nct_id>
  </id_info>
  <brief_title>Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation</brief_title>
  <acronym>ARISTA</acronym>
  <official_title>Randomized Trial of Apixaban vs Dose Adjusted Warfarin in Reducing Rate of Cognitive Function Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Non-valvular Atrial Fibrillation Patients With CHA2DS2-VaSc Score = 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' central hypothesis is that in patients with atrial fibrillation,&#xD;
      anticoagulation with Apixaban reduces the rate of decline in cognitive function, when&#xD;
      compared to Warfarin. The investigators also hypothesize that Apixaban reduces cognitive&#xD;
      decline by reducing the rate of new cerebral infarction and cerebral microbleeds detected by&#xD;
      cerebral MRI compared to warfarin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to slower than anticipated enrollment.&#xD;
  </why_stopped>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Actual">December 15, 2020</completion_date>
  <primary_completion_date type="Actual">December 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized Neurocognitive Function Score</measure>
    <time_frame>Baseline, Year 1, Year 2</time_frame>
    <description>Assess the change in cognitive function using standardized neurocognitive assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI Evidence of Silent Cerebral Infarct</measure>
    <time_frame>Baseline, Year 2</time_frame>
    <description>Magnetic Resonance Imagining of the brain to assess the development of new silent cerebral infarcts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI Evidence of New Cerebral Micro-bleeds</measure>
    <time_frame>Baseline, Year 2</time_frame>
    <description>Magnetic Resonance Imagining of the brain to assess the development of new cerebral micro-bleeds</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Eliquis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Dosage either 5mg or 2.5mg for 2 years</description>
    <arm_group_label>Eliquis</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Dosage assessed by your treating physician for 2 years</description>
    <arm_group_label>Warfarin</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-valvular Atrial Fibrillation&#xD;
&#xD;
          -  CHA2DS2-VASc Score &gt; or = to 2&#xD;
&#xD;
          -  Never been treated with Apixaban (Eliquis) or prior treatment of &lt; 1 month&#xD;
&#xD;
          -  Candidate for oral anticoagulation as assessed by a treating physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Valvular Atrial Fibrillation (Rheumatic valve disease,Moderate or greater mitral&#xD;
             stenosis,Mechanical cardiac valve)&#xD;
&#xD;
          -  Active Bleeding&#xD;
&#xD;
          -  Prior treatment with Apixaban &gt;1 month&#xD;
&#xD;
          -  Recent stroke within 7 days&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Implanted devices not compatible with MRI/any cardiac implanted device&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Active alcohol/drug abuse&#xD;
&#xD;
          -  Life expectancy &lt; 1 year&#xD;
&#xD;
          -  Taking asprin with &gt;100mg doses&#xD;
&#xD;
          -  Known hypersensitivity to warfarin or Apixaban&#xD;
&#xD;
          -  Severe renal insufficiency&#xD;
&#xD;
          -  Prior severe bleeding (Intracranial bleeding (subdural, subarachnoid, intraparenchymal&#xD;
             bleeding),GI bleed requiring transfusion,Bleeding from other sites requiring&#xD;
             transfusion)&#xD;
&#xD;
          -  Psychosocial reasons that make study participation impractical&#xD;
&#xD;
          -  Currently enrolled in another IND or IDE trial that has not completed the primary&#xD;
             endpoint or that clinically interferes with the current study endpoints&#xD;
&#xD;
          -  Co-morbid condition(s) that could limit the subject's ability to participate in the&#xD;
             trial or to comply with follow-up requirements, or that could impact the scientific&#xD;
             integrity of the study.&#xD;
&#xD;
          -  Prisoners or subjects who are involuntarily incarcerated&#xD;
&#xD;
          -  Subjects who are compulsorily detained for treatment of either psychiatric or physical&#xD;
             illness&#xD;
&#xD;
          -  Current or expected systemic treatment with strong dual inhibitors of CYP3A4 and P-gp&#xD;
             (Any one of rifampin, carbamazepine, phenytoin, St. John's Wort, ketoconazole,&#xD;
             itraconazole, ritonavir, clarithromycin)&#xD;
&#xD;
          -  Need for dual anti-platelet therapy with aspirin and another agent such as&#xD;
             thienopyridine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malini Madhavan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <results_first_submitted>February 5, 2021</results_first_submitted>
  <results_first_submitted_qc>February 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2021</results_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Malini Madhavan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Apixaban</keyword>
  <keyword>Warfarin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03839355/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Eliquis</title>
          <description>Apixaban: Dosage either 5mg or 2.5mg for 2 years</description>
        </group>
        <group group_id="P2">
          <title>Warfarin</title>
          <description>Warfarin: Dosage assessed by your treating physician for 2 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eliquis</title>
          <description>Apixaban: Dosage either 5mg or 2.5mg for 2 years</description>
        </group>
        <group group_id="B2">
          <title>Warfarin</title>
          <description>Warfarin: Dosage assessed by your treating physician for 2 years</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.4" spread="5.84"/>
                    <measurement group_id="B2" value="76.4" spread="5.61"/>
                    <measurement group_id="B3" value="76.9" spread="5.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Standardized Neurocognitive Function Score</title>
        <description>Assess the change in cognitive function using standardized neurocognitive assessment.</description>
        <time_frame>Baseline, Year 1, Year 2</time_frame>
        <population>Study terminated due to slower than anticipated enrollment. Data was not collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Eliquis</title>
            <description>Apixaban: Dosage either 5mg or 2.5mg for 2 years</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin: Dosage assessed by your treating physician for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Neurocognitive Function Score</title>
          <description>Assess the change in cognitive function using standardized neurocognitive assessment.</description>
          <population>Study terminated due to slower than anticipated enrollment. Data was not collected or analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MRI Evidence of Silent Cerebral Infarct</title>
        <description>Magnetic Resonance Imagining of the brain to assess the development of new silent cerebral infarcts.</description>
        <time_frame>Baseline, Year 2</time_frame>
        <population>Study terminated due to slower than anticipated enrollment. Data was not collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Eliquis</title>
            <description>Apixaban: Dosage either 5mg or 2.5mg for 2 years</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin: Dosage assessed by your treating physician for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Evidence of Silent Cerebral Infarct</title>
          <description>Magnetic Resonance Imagining of the brain to assess the development of new silent cerebral infarcts.</description>
          <population>Study terminated due to slower than anticipated enrollment. Data was not collected or analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MRI Evidence of New Cerebral Micro-bleeds</title>
        <description>Magnetic Resonance Imagining of the brain to assess the development of new cerebral micro-bleeds</description>
        <time_frame>Baseline, Year 2</time_frame>
        <population>Study terminated due to slower than anticipated enrollment. Data was not collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Eliquis</title>
            <description>Apixaban: Dosage either 5mg or 2.5mg for 2 years</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin: Dosage assessed by your treating physician for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Evidence of New Cerebral Micro-bleeds</title>
          <description>Magnetic Resonance Imagining of the brain to assess the development of new cerebral micro-bleeds</description>
          <population>Study terminated due to slower than anticipated enrollment. Data was not collected or analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from baseline to end of treatment for approximately 24 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Eliquis</title>
          <description>Apixaban: Dosage either 5mg or 2.5mg for 2 years</description>
        </group>
        <group group_id="E2">
          <title>Warfarin</title>
          <description>Warfarin: Dosage assessed by your treating physician for 2 years</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Malini Madhavan</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-255-4152</phone>
      <email>Madhavan.Malini@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

